University College London
London, EC1V 9EL, United Kingdom
Location contact
Annegret Dahlmann-Noor, PhD
CONTACT
Annegret Dahlmann-Noor, PhD
CONTACT
NCT Number: NCT06771258
In this project the research team will begin to find out whether shining a red LED light at the eyes can slow down the worsening of short-sightedness in children.
This is important, because short-sightedness now starts at a younger age and worsens faster than in the past. Many people are at risk of permanently losing their eyesight in middle-age because of short-sightedness.
The researchers plan to use red LED light, which is safe to use. Red-light treatment improves the blood flow at the back of the eye, in a layer called "choroid", which can be measured on eye-scans. The team have done a study with healthy adults, which showed that red-light is safe and gently improves the blood flow at the back of the eye. In adults, this has no effect on myopia, because their eyes are fully grown. In children, red-light may slow down myopia, and in this project, the researchers want to find out which level of red-light is needed to have this effect. The researchers will ask 24 children age 5-12 years to use red-light for three minutes twice a day for three months. Three will be 4 groups of children, and each group will use a different level of brightness. The researchers will measure the eye length and the thickness of the choroid at the start and 1 and 3 months later and compare the change in eye length between the different groups.
In practice, children will need to use the treatment for several years. The researchers will use the results of this study to prepare a longer study with more children.
Trial opening soon.
Get Notified5 year–12 year
All sexes
Interventional
Not applicable
London, EC1V 9EL, United Kingdom
Annegret Dahlmann-Noor, PhD
CONTACT
Annegret Dahlmann-Noor, PhD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Red LED light
Time frame: 3 months
The researchers will measure the length of the eyeballs using an optical biometer; these are the most sensitive outcome measure in myopia studies, and the least invasive measurement method.
Time frame: 3 months
The team will measure the refractive error (prescription for spectacles) using an open-view autorefractor, as a secondary measure of myopia progression.
Time frame: 3 months
The team will acquire an optical coherence tomography scan. On the scan, the researchers will measure the choroidal thickness, which is frequently used as a proxy measure of the treatment effect of interventions to slow myopia progression. The choroid is a vascular layer underneath the retina at the back of the eye.
Time frame: 3 months
As a safety measure, the researchers will measure colour contrast sensitivity on a computer-screen, showing participants coloured symbols on a grey background. This is the most sensitive test for photoreceptor health, the layer of cells in the retina which change light signals to electrical signals.
Time frame: 3 months
As a secondary safety outcome, the researchers will measure the participant's visual acuity, using a test where participants read letters of reducing size on a chart.
Time frame: 3 months
The researchers will ask participants open-ended questions about their thoughts and experience with using red-light treatment, and about easier ways for children to use it.
Contact information is provided by the study sponsor or research team.
University College, London
Other
What Effect Does Looking At Red Light Have on the Eye in Children and Young People? - a Proof-of-concept Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724210
Eye Diseases, Myopia
Beijing, Beijing Municipality, China
View Trial DetailsNCT07406906
Eye Diseases, Myopia
Hong Kong
View Trial DetailsNCT07721714
Astigmatism, Eye Diseases
Palo Alto, California, United States
View Trial DetailsNCT07696468
Eye Diseases, Myopia
Guangzhou, Guangdong, China
View Trial Details